Russia Targets Import Substitution for Autoimmune and Dementia Therapies

The city of Saransk, the capital of Russia's Mordovia Republic, is evolving into a specialized pharmaceutical hub through a structural merger of industrial production and academic training. The Biokhimik plant, part of the Promomed group, has integrated its manufacturing cycle with the Ogarev Mordovia State University (MSU), shifting from simple scholarship grants to a system of direct workforce management and joint drug development. From Education to Production Line The relationship between the university and the plant now operates on a direct-order basis for personnel. Students train on active synthesis and biotechnological production lines, removing the need for post-graduation adaptation. Current employment data highlights the plant's role as a primary employer for the region's technical graduates: